Last Updated: September 24, 2026

Details for New Drug Application (NDA): 204230

✉ Email this page to a colleague

« Back to Dashboard

NDA 204230 describes BENDAMUSTINE HYDROCHLORIDE, which is a drug marketed by Accord Hlthcare, Apotex, Breckenridge, Dr Reddys, Eugia Pharma, Meitheal, Nang Kuang Pharm Co, Pharmobedient, Avyxa Holdings, Baxter Hlthcare Corp, and Hospira, and is included in twelve NDAs. It is available from seven suppliers. Additional details are available on the BENDAMUSTINE HYDROCHLORIDE profile page.

The generic ingredient in BENDAMUSTINE HYDROCHLORIDE is bendamustine hydrochloride. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.

Summary for 204230

Tradename:	BENDAMUSTINE HYDROCHLORIDE
Applicant:	Apotex
Ingredient:	bendamustine hydrochloride
Patents:	0

Medical Subject Heading (MeSH) Categories for 204230

Antineoplastic Agents, Alkylating

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	POWDER;INTRAVENOUS			Strength	25MG/VIAL
Approval Date:	Jun 5, 2023	TE:		RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	POWDER;INTRAVENOUS			Strength	100MG/VIAL
Approval Date:	Jun 5, 2023	TE:		RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.